Tradestie Institutional Equity Comparison Engine

MNOV vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while MNOV counters with relative strength in Valuation. Fundamentally, MNOV trades at 8.5x Forward P/E with -1232.2% operating margin (+12.4% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNOV
MNOV 8.5x vs SRZN N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -1232.2% vs -485.4% ยท YoY +12.4% vs +408.6%
Momentum & Technical Winner SRZN
1Y -8.4% vs +110.8% ยท 52W Pos 3% vs 63%
Options & Structure Winner SRZN
UNCLASSIFIED (50th %ile IV) vs CONSOLIDATION (13th %ile IV)
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
1M Return +10.52%
1Y Return +110.81%
Forward P/E N/M
Unified AI Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MNOV -8.39% SRZN +110.81% Spread: +119.2 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MNOV Revenue SRZN Revenue MNOV Op. Margin SRZN Op. Margin Margin Edge
FY2012 $0M N/A -1363.8% N/A MNOV
FY2021 $0M N/A -253.0% N/A MNOV
FY2022 N/A $10M N/A -354.7% SRZN
FY2023 $0M N/A -990.0% N/A MNOV
FY2024 N/A $10M N/A -239.7% SRZN
FY2025 $0M $0M -3242.5% -1210.6% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MNOV (5) vs SRZN (4)
Institutional Metric MNOV SRZN Criterion Row Winner
Market Capitalization Scale $65.1M $642.7M Larger Scale SRZN
Trailing P/E Ratio Valuation 8.5x N/M Lower Multiple MNOV
Forward P/E Ratio Valuation 8.5x N/M Lower Multiple MNOV
Revenue Growth (YoY) Growth +12.4% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability -1232.2% -485.4% Higher Margin SRZN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -24.8% -62.8% Higher ROE MNOV
52-Week Range Position Momentum 3% ($1โ€“$4) 63% ($13โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 0.59ฮฒ ยท 38% Vol 1.29ฮฒ ยท 73% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 50.2 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite MNOV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MNOV vs SRZN Buy Guide
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MNOV nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.